Imunon Inc
Veridion Score
Composite trend over time
Why is IMNN moving today?
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IMNN.
IMNN insider activity
Imunon Inc
8 insiders bought in the last 90 days
Net buying: $220K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-06 | Eylward Susan | Insider | sell | $1.88 | 920 | 2,896 | $2K | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Faller Douglas Vincent | Insider | buy | $1.91 | 1,308 | 23,204 | $2K | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Eylward Susan | Insider | buy | $1.91 | 920 | 3,816 | $2K | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Lindborg Stacy | Insider | buy | $1.91 | 2,534 | 76,722 | $5K | SEC Form 4 |
| 2026-07-07 | 2026-07-02 | Tardugno Michael H | Insider | buy | $1.91 | 4,410 | 64,396 | $8K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 14 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moIMNN contract awards, year to date.
Public federal awards linked to this ticker.
IMNN lobbying filings, year to date.
Registered lobbying filings matched to Imunon Inc.